Loading company financials…
NYSE · Surgical & Medical Instruments & Apparatus · CIK 0000885725
$47.80
+2.05% · delayed 15 min
$70.54B market value
What this company does
BOSTON SCIENTIFIC makes medical devices and equipment. It took in $20.07B last year, which makes it a large company. Of every dollar it sells, about 14 cents is left as profit.
Financial health
Strong finances across the board.
From BOSTON SCIENTIFIC CORP's FY2025 annual filing · share price scored separately
Every check behind the three models, and what each one tests
Measured against FY2024, from the 10-K
Improved: +19.9%
$16.75B to $20.07B
Improved: +56.7%
$1.85B to $2.89B
Improved: +3.4 pts
11.0% to 14.4%
It makes a profit rather than burning through money.
$2.89B earned last year
Day-to-day operations generate real cash, not just accounting profit.
$4.53B cash from operations
Sales are growing quickly.
up 19.9% on last year
It holds more cash than debt, so borrowings are not a pressure.
$1.67B more cash than debt
Nothing in the filings stands out as a concern.
Filter by minute, hour, day or week
Loading price history…
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 5% a year for the next 10 years. Over the last 10 years it grew by about 23% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 14 cents of every dollar of sales as profit, earning $2.89B last year.
What it earns, what it keeps, and what it costs to run — all from the same filing
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it earned $2.89B and generated $4.53B of cash from operations.
Reported annual figures
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Nothing recent
No insider trades, pending-sale notices or 5% stake filings from BSX in the last few months. That is the ordinary case, not a gap.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Go deeper
Every figure above traces back to one of these filings.
Straight from SEC EDGAR — the original source for every figure above
| Filing | Filed | Covers to |
|---|---|---|
| Major event announcement(8-K) | 2026-08-26 | 2026-08-26 |
| Quarterly report(10-Q) | 2026-08-03 | 2026-06-30 |
Financial figures are from BSX's 10-K for fiscal year 2025 (period ending 2025-12-31), reported under the US GAAP taxonomy. View the source filing. Total liabilities were not tagged directly and were calculated as assets minus equity.
8 of 8 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's. One could not be evaluated and is excluded from the total rather than counted as a failure.
3.18
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
not reported — This company has not reported enough of the required figures to calculate this score.
This company has not reported enough of the required figures to calculate this score.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: +38.3%
$2.65B to $3.66B
Improved: +374.6%
$414.0M to $1.97B
Changed: +10.9%
$790.0M to $876.0M
2 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Nothing here reads the management commentary, which is where a company explains its own numbers.
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 3% and 7%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 1.9% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
Yes, quickly. Sales grew 19.9% last year.
No — it holds more cash than debt, with $1.67B left over after paying off every borrowing. For every $1 it owes, it owns $2.25 in assets.
Around average. Investors pay $24.4 for every $1 of yearly profit.
This company has not reported enough of the required figures to calculate this score.
At a glance
| Major event announcement(8-K) | 2026-07-29 | 2026-07-29 |
| Major event announcement(8-K) | 2026-07-27 | 2026-07-21 |
| Major event announcement(8-K) | 2026-05-18 | 2026-05-18 |
| Major event announcement(8-K) | 2026-05-18 | 2026-05-18 |
| Major event announcement(8-K) | 2026-05-05 | 2026-04-30 |
| Quarterly report(10-Q) | 2026-05-01 | 2026-03-31 |
| Major event announcement(8-K) | 2026-04-22 | 2026-04-22 |
| Major event announcement(8-K) | 2026-03-30 | 2026-03-28 |
| Shareholder voting information(DEF 14A) | 2026-03-18 | 2026-03-18 |
| Major event announcement(8-K) | 2026-02-26 | 2026-02-26 |
| Major event announcement(8-K) | 2026-02-23 | 2026-02-18 |
| Annual report(10-K) | 2026-02-17 | 2025-12-31 |
| Major event announcement(8-K) | 2026-02-05 | 2026-02-02 |
| Major event announcement(8-K) | 2026-02-04 | 2026-02-04 |
| Major event announcement(8-K) | 2026-01-15 | 2026-01-14 |
| Major event announcement(8-K) | 2026-01-15 | 2026-01-15 |
| Major event announcement(8-K) | 2025-11-19 | 2025-11-18 |
| Quarterly report(10-Q) | 2025-11-03 | 2025-09-30 |
Coverage from the last 30 days
Boston Scientific begins to restore shipping after cyberattack
Yahoo Finance ·
Did Recalls And Cyberattack Disruptions Just Shift Boston Scientific's (BSX) Investment Narrative?
Yahoo Finance ·
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors
Yahoo Finance ·
Boston Scientific (BSX) Stock Looks Cheap After a 55% Slump
Yahoo Finance ·
Cyberattack & Weak 2026 Outlook Weigh on BSX: Is the Stock a Sell?
Yahoo Finance ·
The Wide Divide Priced Into Boston Scientific Stock
Yahoo Finance ·
2 Reasons to Watch BSX and 1 to Stay Cautious
Yahoo Finance ·
How Is Boston Scientific's Stock Performance Compared to Other Medical Device Stocks?
Yahoo Finance ·
The Peer-Group Mispricing Sitting On BSX Stock
Yahoo Finance ·
Boston Scientific (BSX) Up 1.5% Since Last Earnings Report: Can It Continue?
Yahoo Finance ·
ISRG's Ion Platform Is Quietly Becoming a Second Growth Engine
Yahoo Finance ·
How Much Upside Can BSX Stock's Growth Deliver?
Yahoo Finance ·
Primary sources and further research